0.1 (7.636%)
ASX:Live
Short Term
Mean Reversion
Very Strong
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Valuation
Value
Consensus
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9639.6036
Address
Level 38 55 Collins Street Melbourne, Victoria (VIC) 3000
Description
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.25 - 1.58
Trade Value (12mth)
US$937,074.00
1 week
-5.17%
1 month
48.65%
YTD
350.82%
1 year
302.83%
All time high
9.42
EPS 3 yr Growth
-42.50%
EBITDA Margin
-917.70%
Operating Cashflow
-$56m
Free Cash Flow Return
-9.50%
ROIC
-15.00%
Interest Coverage
-2.40
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
1088m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
3.37
| Date | Announcements |
|---|---|
|
11 October 24 |
Notification regarding unquoted securities - MSB
×
Notification regarding unquoted securities - MSB |
|
11 October 24 |
Notification of cessation of securities - MSB
×
Notification of cessation of securities - MSB |
|
10 October 24 |
Change in substantial holding
×
Change in substantial holding |
|
09 October 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
|
30 September 24 |
Mesoblast Option to Issue up to US$50m Convertible Notes
×
Mesoblast Option to Issue up to US$50m Convertible Notes |
|
30 September 24 |
Proposed issue of securities - MSB
×
Proposed issue of securities - MSB |
|
27 September 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
|
17 September 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
|
29 August 24 |
Preliminary Final Report including Appendix 4E
×
Preliminary Final Report including Appendix 4E |
|
29 August 24 |
Annual Financial Results Presentation
×
Annual Financial Results Presentation |
|
29 August 24 |
MSB Annual Financial Results and Operational Update
×
MSB Annual Financial Results and Operational Update |
|
28 August 24 |
Mesoblast 2024 Full Year Financial Results Webcast
×
Mesoblast 2024 Full Year Financial Results Webcast |
|
21 August 24 |
Class Action Resolution
×
Class Action Resolution |
|
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
23 July 24 |
FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
×
FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L |
|
22 July 24 |
Confirmatory Phase 3 Back Pain Trial Actively Enrols
×
Confirmatory Phase 3 Back Pain Trial Actively Enrols |
|
12 July 24 |
Change in substantial holding
×
Change in substantial holding |
|
12 July 24 |
Notification of cessation of securities - MSB
×
Notification of cessation of securities - MSB |
|
12 July 24 |
Notification regarding unquoted securities - MSB
×
Notification regarding unquoted securities - MSB |
|
12 July 24 |
Appendix 3Y for Philip Krause
×
Appendix 3Y for Philip Krause |
|
09 July 24 |
Mesoblast Resubmits BLA with FDA for Ryoncil Approval
×
Mesoblast Resubmits BLA with FDA for Ryoncil Approval |
|
01 July 24 |
Mesoblast to File BLA for Ryoncil FDA Approval Next Week
×
Mesoblast to File BLA for Ryoncil FDA Approval Next Week |
|
03 June 24 |
Corporate Presentation
×
Corporate Presentation |
|
03 June 24 |
Mesoblast Corporate Presentation at Investor Conference
×
Mesoblast Corporate Presentation at Investor Conference |
|
10 May 24 |
Appendix 3Y for Eric Rose
×
Appendix 3Y for Eric Rose |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
